Focus: GE HealthCare is a diagnostic imaging and monitoring company with 940 active job openings, operating as a publicly-traded healthcare technology enterprise. They lead in contrast media, nuclear imaging agents, and diagnostic ultrasound/MRI platforms.
Profile data last refreshed 12h ago · AI intelligence enriched 3w ago
Hot — 795 jobs added in 30d
Net +97 (795 new, 698 removed). Aggressive expansion phase.
Best fit for professionals seeking stable, large-company diagnostic innovation roles with strong engineering/manufacturing components; less ideal for those targeting cutting-edge therapeutic drug development.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Leading X-ray contrast agent facing imminent exclusivity loss; significant revenue vulnerability likely driving commercial strategy shifts.
Help build intelligence for GE HealthCare
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from GE HealthCare's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
A2A adenosine receptor agonist already post-loss of exclusivity; established utility in cardiac stress testing but facing generic competition.
Gadolinium contrast agent now generic; stable revenue base but limited growth prospects in mature MRI contrast market.
Iso-osmolar contrast medium with established safety profile; post-LOE but maintains steady demand in interventional cardiology.
46 discontinued, 14 duplicate formulations not shown
8-K Filing: Parker-Hannifin Corp (PH) (CIK 0000076334) — 8-K
8-K
8-K Filing: Covista Inc. (ATGE) (CIK 0000730464) — EX-99.1
EX-99.1
8-K Filing: Bravo Multinational Inc. (BRVO) (CIK 0001444839) — CURRENT REPORT
CURRENT REPORT
8-K Filing: GE HealthCare Technologies Inc. (GEHC) (CIK 0001932393) — EX-99
EX-99
8-K Filing: ADOBE INC. (ADBE) (CIK 0000796343) — EX-10.1
EX-10.1
8-K Filing: Sensus Healthcare, Inc. (SRTS) (CIK 0001494891) — EXHIBIT 99.1
EXHIBIT 99.1
Showing 6 of 9 news items
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo